Spotlight Stories

  1. CEO Q&A: David Younger, Ph.D. 1/5/2024

    Life Science Leader catches up with David Younger, co-founder and CEO of A-Alpha Bio, about the promise of molecular glues, the challenges of starting up a new company, and collaborating with Big Pharma.

  2. Ahead Of The Curve On Radiopharmaceuticals 1/1/2024

    Former president of Cardinal Health’s nuclear and precision health solutions group Tiffany Olson discusses her work on Bayer's Xofigo, and how she anticipated the rise of radiopharmaceuticals.

  3. Neurvati Maps Path To Neuroscience Approvals 1/1/2024

    Can a nested financial model help bring the next generation of neuroscience treatments to patients?

  4. Finance And Funding Outlook 2024: Additional Responses 12/14/2023

    Additional 2024 Outlook responses from biopharma leaders on finance and funding topics.

  5. Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place 12/1/2023

    Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024.

  6. Executive Outlook: Converting Innovative Science Into Predictable Returns 12/1/2023

    Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape.

  7. Finance And Funding: Anticipating Improvement, Planning For Uncertainty 12/1/2023

    Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.

  8. Biopharma's Eminent Challenges In 2024 — Inside & Out 12/1/2023

    A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.

  9. Building A Business Model For Novel Antibiotics 11/1/2023

    In the challenging development space for novel antibiotics, Spero Therapeutics is using partnership, external validation, and formulation science to develop drugs treating bacterial infections both rare and common.

  10. The Power Couple Behind Krystal Biotech 11/1/2023

    Krish and Krishnan, the husband-and-wife team that founded and leads Krystal Biotech, cleared a path to market for the first ever topical and redosable gene therapy.